History

September 2002: Establishes in Shanghai, China
Support and capital from Hutchison Whampoa Limited (now CK Hutchison)
Initiates botanical drug R&D programs
April 2005: Initiates new chemical entity (NCE) drug discovery program
May 2005:  Files first Investigational New Drug (IND) application with the US Food & Drug Administration (US FDA)
May 2006: Parent company Hutchison China MediTech Limited (Chi-Med) successfully completes its initial public offering on London’s Alternative Investment Market
November 2006: Initiates oncology collaboration with Merck AG
September 2007: Initiates first collaboration with Eli Lilly
December 2008: Initiates immunology collaboration with Johnson & Johnson
October 2009: First NCE enters phase I clinical trial in Australia
November 2009: Successfully completes HMPL-004 global Phase II clinical trial for ulcerative colitis
May 2010: HMPL-004 Distinguished Plenary Presentation at Digestive Disease Week
Sulfatinib receives SFDA Green Channel approval and begins Phase I clinical trial in China
November 2010: Received venture capital investment
January 2011:  Fruquinitinib enters first-in-human Phase I clinical trial in China
November 2011:  Epitinib initiates first-in-human Phase I clinical trial in China
December 2011: AstraZeneca and Hutchison Medi Pharma Enter into Global Collaboration to Co-Develop and Commercialize Novel Cancer Therapy
March 2012: HMP initiates Phase I clinical study of its novel c-Met inhibitor Savolitinib
November 2012: HMP initiates Phase I clinical study with novel EGFR inhibitor Theliatinib
November 2012: HMP establishes joint venture with Nestlé Health Science
October 2013: Cancer Therapy Collaboration with Lilly
July 2015:  VC exchanges shares in HMP for shares in Chi-Med
March 2016:  Chi-Med successfully completes its additional public offering on NASDAQ